Recce Pharma reports positive Phase II trial of RECCE 327 Gel

19 February 2025

Australia’s Recce Pharmaceuticals (ASX: RCE) has announced positive data from a Phase II trial evaluating RECCE 327 Topical Gel (R327G) for the treatment of acute bacterial skin and skin structure infections (ABSSSI), with the news pushing the firm’s shares up around 9%.

“These impressive results underscore the potential of our topical gel to meet critical unmet medical needs in infection treatment, said James Graham, chief executive of Recce Pharmaceuticals, adding: “As we advance towards registrational Phase III trials in Indonesia and Australia, we are encouraged by the rapid efficacy and strong safety outcomes demonstrated in this study.

Market potential

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK